CSL Net Current Debt 2017-2024 | CSLLY

CSL net current debt for the twelve months ending December 31, 2024 was $-0.270B, a 126.34% increase year-over-year.

  • CSL annual net current debt for 2024 was $-0.099B, a 23.75% increase from 2023.
  • CSL annual net current debt for 2023 was $-0.08B, a 60% increase from 2022.
  • CSL annual net current debt for 2022 was $-0.05B, a 22.48% decline from 2021.

CSL Net Current Debt 2017-2024 | CSLLY

  • CSL annual net current debt for 2024 was $-0.099B, a 23.75% increase from 2023.
  • CSL annual net current debt for 2023 was $-0.08B, a 60% increase from 2022.
  • CSL annual net current debt for 2022 was $-0.05B, a 22.48% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B
Repligen (RGEN)$7.5B